Neumora Therapeutics, Inc. (NMRA): Total Liabilities
$87.18M
As of 2025-12-31
$80.73M
As of 2026-06-30
+43.7%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $87.18M | +191.5% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $29.91M | +10.3% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $27.12M | -7.7% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $29.40M | n/a | 2024-03-07, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $87.18M | +191.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $8.30M | +122.3% |
| Instil Bio, Inc. (TIL) | 2025-12-31 | $89.66M | -4.8% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $53.19M | -11.9% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $13.06M | -8.8% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $21.32M | +17.0% |
Compare NMRA, EDIT, VXRT, IKT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗